Safety and efficacy of levofloxacin 750mg for 2 weeks or 3 weeks compared with levofloxacin 500mg for 4 weeks in treating chronic bacterial prostatitis

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1433-1441

  Paglia, Margaret ^a   Peterson, Janet ^a   Fisher, Alan C ^a   Qin, Zhihai ^a   Nicholson, Susan C ^a   Kahn, James B ^b  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

^b JBK Strategic Consultations   (United States)

Author keywords

Chronic bacterial prostatitis; Fluoroquinolone; Infection; Levofloxacin

Indexed keywords

LEVOFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE PAIN; CHRONIC BACTERIAL PROSTATITIS; CHRONIC PROSTATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SUICIDAL IDEATION; SYNCOPE; TENDINITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PROSTATITIS; TREATMENT OUTCOME;

EID: 77952468728     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003795030     Document Type: Article

References (23)

1. Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother 2007;8: 1667-1674
2. Naber KG, Sorgel F. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35:331-335
3. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008;68:535-565
4. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-119
5. Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? Am J Med 1999;106:327-334
6. Naber KG, Busch W, Focht J. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. Int J Antimicrob Agents 2000;14:143-149
7. Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multi-center study. Urology 2003;62:537-541
8. Naber KG. Management of bacterial prostatitis: what's new? BJU Int 2008;101(Suppl 3):7-10
9. Drusano GL, Preston SL, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000;44:2046-2051
10. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquino-lone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosoco-mial pneumonia. J Infect Dis 2004;189:1590-1597
11. Poole M, Anon J, Paglia M, et al. A trial of high-dose, short-course levoflox-acin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 2006;134:10-17
12. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levo-floxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-760
13. Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25:1001-1010
14. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008;71:17-22
15. Gilbert DN, Moellering Jr RC, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy 2008. Antimicrobial Therapy, 2008
16. Naber KG, Weidner W. Chronic prostatitis-an infectious disease? J Antimicrob Chemother 2000;46:157-161
17. Soto SM, Smithson A, Martinez JA, et al. Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance. J Urol 2007;177:365-368
18. Roberts RO, Lieber MM, Bostwick DG, et al. A review of clinical and pathological prostatitis syndromes. Urology 1997;49:809-821
19. Terai A, Yamamoto S, Mitsumori K, et al. Escherichia coli virulence factors and serotypes in acute bacterial prostatitis. Int J Urol 1997;4:289-294
20. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France: World Medical Association. Available at: http://www.wma.net/en/30publications/10policies/b3/index. html [Last accessed 23 July 2009]
21. Guideline for Good Clinical Practice. London, England: European Medicines Agency 2002. Available at: http://www.emea.europa.eu/pdfs/human/ich/013595en. pdf [Last accessed 23 July 2009]
22. Litwin MS, McNaughton-Collins M, Fowler Jr FJ, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369-375
23. Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med 2003;22:2429-2441